Journal of Medicinal Chemistry · 2024 · 25 citations · 48 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryHit-to-lead OptimizationLigand BindingPotency OptimizationAcute Myeloid Leukemia TherapyAnticancer ActivityBromodomain InhibitionG1 Cell-cycle ArrestG1 Phase ArrestHuman Ether-a-go-go-related Gene (Herg) Channel InhibitionIon Channel SelectivitySelectivity
Bromodomain-selective BET inhibition has emerged as a promising strategy to improve the safety profiles of pan -BET inhibitors. Herein, we report the discovery of potent phenoxyaryl pyridones as highly BD2-selective BET inhibitors. Compound 23 (IC 50 = 2.9 nM) exhibited a comparable BRD4 BD2 inhibitory activity relative to 10 (IC 50 = 1.0 nM) and remarkably improved selectivity over BRD4 BD1 ( 23: 2583-fold; 10: 344-fold). This lead compound significantly inhibited the proliferation of acute myeloid leukemia (AML) cell lines through induction of G0/G1 arrest and apoptosis in vitro . Excellent in vivo antitumor efficacy with 23 was achieved in an MV;411 mouse xenograft model. Pleasingly, compound 23 (hERG IC 50 > 30 μM) mitigated the inhibition of the human ether-à-go-go-related gene (hERG) ion channel compared with 10 (hERG IC 50 = 2.8 μM). This work provides a promising BD2-selective lead for the development of more effective and safe BET inhibitors as anticancer agents.
48
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text